215 related articles for article (PubMed ID: 12505241)
1. Surrogate markers and joint models for longitudinal and survival data.
Taylor JM; Wang Y
Control Clin Trials; 2002 Dec; 23(6):626-34. PubMed ID: 12505241
[TBL] [Abstract][Full Text] [Related]
2. Statistical challenges in the evaluation of surrogate endpoints in randomized trials.
Molenberghs G; Buyse M; Geys H; Renard D; Burzykowski T; Alonso A
Control Clin Trials; 2002 Dec; 23(6):607-25. PubMed ID: 12505240
[TBL] [Abstract][Full Text] [Related]
3. Alternative methods to evaluate trial level surrogacy.
Abrahantes JC; Shkedy Z; Molenberghs G
Clin Trials; 2008; 5(3):194-208. PubMed ID: 18559408
[TBL] [Abstract][Full Text] [Related]
4. A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials.
Molenberghs G; Burzykowski T; Alonso A; Assam P; Tilahun A; Buyse M
Stat Methods Med Res; 2010 Jun; 19(3):205-36. PubMed ID: 19608602
[TBL] [Abstract][Full Text] [Related]
5. A new proportion measure of the treatment effect captured by candidate surrogate endpoints.
Kobayashi F; Kuroki M
Stat Med; 2014 Aug; 33(19):3338-53. PubMed ID: 24782344
[TBL] [Abstract][Full Text] [Related]
6. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
Methy N; Bedenne L; Bonnetain F
BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
[TBL] [Abstract][Full Text] [Related]
7. Novel procedures for validating surrogate endpoints in clinical trials.
Cleophas TJ; Zwinderman AH; Chaib AH
Curr Clin Pharmacol; 2007 May; 2(2):123-8. PubMed ID: 18690859
[TBL] [Abstract][Full Text] [Related]
8. Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas.
Abel UR; Jensen K; Karapanagiotou-Schenkel I; Kieser M
J Biopharm Stat; 2015; 25(6):1285-311. PubMed ID: 25629760
[TBL] [Abstract][Full Text] [Related]
9. Exploring the relationship between the causal-inference and meta-analytic paradigms for the evaluation of surrogate endpoints.
Van der Elst W; Molenberghs G; Alonso A
Stat Med; 2016 Apr; 35(8):1281-98. PubMed ID: 26612787
[TBL] [Abstract][Full Text] [Related]
10. Bayesian estimation of the proportion of treatment effect captured by a surrogate marker.
Cowles MK
Stat Med; 2002 Mar; 21(6):811-34. PubMed ID: 11870819
[TBL] [Abstract][Full Text] [Related]
11. Quantifying the feasibility of shortening clinical trial duration using surrogate markers.
Wang X; Cai T; Tian L; Bourgeois F; Parast L
Stat Med; 2021 Dec; 40(28):6321-6343. PubMed ID: 34474500
[TBL] [Abstract][Full Text] [Related]
12. A systematic comparison of recurrent event models for application to composite endpoints.
Ozga AK; Kieser M; Rauch G
BMC Med Res Methodol; 2018 Jan; 18(1):2. PubMed ID: 29301487
[TBL] [Abstract][Full Text] [Related]
13. An entropy-based nonparametric test for the validation of surrogate endpoints.
Miao X; Wang YC; Gangopadhyay A
Stat Med; 2012 Jun; 31(14):1517-30. PubMed ID: 22344829
[TBL] [Abstract][Full Text] [Related]
14. A measure of the proportion of treatment effect explained by a surrogate marker.
Wang Y; Taylor JM
Biometrics; 2002 Dec; 58(4):803-12. PubMed ID: 12495134
[TBL] [Abstract][Full Text] [Related]
15. Quantifying the effect of the surrogate marker by information gain.
Qu Y; Case M
Biometrics; 2007 Sep; 63(3):958-62; author reply 962-3. PubMed ID: 17825025
[TBL] [Abstract][Full Text] [Related]
16. How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials.
Sofeu CL; Rondeau V
PLoS One; 2020; 15(1):e0228098. PubMed ID: 31990928
[TBL] [Abstract][Full Text] [Related]
17. Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.
Conlon AS; Taylor JM; Elliott MR
Biostatistics; 2014 Apr; 15(2):266-83. PubMed ID: 24285772
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes.
Molenberghs G; Geys H; Buyse M
Stat Med; 2001 Oct; 20(20):3023-38. PubMed ID: 11590630
[TBL] [Abstract][Full Text] [Related]
19. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
Sertdemir Y; Burgut R
Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
[TBL] [Abstract][Full Text] [Related]
20. Statistical controversies in clinical research: an initial evaluation of a surrogate end point using a single randomized clinical trial and the Prentice criteria.
Heller G
Ann Oncol; 2015 Oct; 26(10):2012-6. PubMed ID: 26254442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
